Primary open-angle glaucoma is a progressive eye disease that can lead to irreversible vision loss without timely treatment and ongoing monitoring. This course reviews practical approaches to glaucoma management, including treatment goals, common medication options, and factors that influence adherence and long-term disease control. You will be better prepared to support patients receiving glaucoma therapy through medication counseling, adherence support, and reinforcement of appropriate follow-up care.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpact
GUEST
Stephanie Conway-Allen, PharmD
Associate Professor of Pharmacy Practice,
Massachusetts College of Pharmacy and Health Sciences -Worcester/Manchester
GET CE FOR LISTENING!
Stay Compliant. Grow Clinically. Practice with Confidence.
Pharmacist CE Subscription: All your CE in one convenient subscription.
All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!
The Pharmacist CE Subscription includes:
- Compliance and licensure CE
- GameChangers Clinical Updates
- Practical continuing education across patient care topics
*The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training.
Purchase Now!
PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe treatment goals and common management strategies for primary open-angle glaucoma.
2. Explain pharmacist-relevant considerations for counseling and supporting patients receiving glaucoma therapy.
Rachel Maynard and Stephanie Conway-Allen have no relevant financial relationships to disclose.
0.075 CEU/0.75 Hr
UAN: 0107-0000-26-252-H01-P
Initial release date: 7/20/2026
Expiration date: 7/20/2029
Additional CPE details can be found here.
Follow CEimpact on Social Media:
LinkedIn
Instagram
